Despite the fact that available agents targeting HVEM/BTLA have shown encouraging results in epithelial ovarian carcinoma and chronic lymphocytic leukemia (40, 41), there is no published study to evaluate the therapeutic efficacy of HVEM/BTLA inhibition in NSCLC. This evidence concerns the gene BTLA and B-cell chronic lymphocytic leukemia.